BRAF and melanoma: However, this impairment of WNT5A signaling appears to trigger a compensatory mechanism to maintain the invasive migration of BRAF wild‐type and BRAFV600 mutated melanoma cells treated with a BRAF inhibitor, through a RND3‐RhoA‐induced transition from a mesenchymal to an amoeboid mode of invasion.